Literature DB >> 10216467

Successful treatment of decompensated chronic viral hepatitis by bursal disease virus vaccine.

L K Csatary1, R Schnabel, T Bakács.   

Abstract

Three cases of women with chronic liver inflammation caused by hepatitis B (two) and C (one) viral infections, were followed up to twelve years after diagnosis. As conventional therapy was ineffective and the patients progressed into decompensated liver disease, they were superinfected with massive doses of an attenuated variant (MTH-68/B) of the apathogenic avian Bursal Disease virus (a double-stranded RNA virus from the Birnaviridae family). Clinical symptoms and biochemical abnormalities were resolved in two patients following few months of virus treatment. Cirrhosis was stabilized and significant clinical improvement was achieved in the third patient--who before the virus therapy was moribund with recurring, diuretic-resistant ascites, variceal bleedings, portal encephalopathy and renal failure. To our knowledge, these are the first recorded cases of decompensated chronic viral hepatitis which went to long-lasting remission or were stabilized by superinfection with an apathogenic virus.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10216467

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  4 in total

1.  Recombinant infectious bursal disease virus carrying hepatitis C virus epitopes.

Authors:  Chitra Upadhyay; Arun Ammayappan; Deendayal Patel; Imre Kovesdi; Vikram N Vakharia
Journal:  J Virol       Date:  2010-11-24       Impact factor: 5.103

2.  Healing of Severe Herpes Zoster Ophthalmicus Within a Few Days: An Autobiographical Case Report.

Authors:  Tibor Bakacs
Journal:  Cureus       Date:  2021-12-09

3.  An Orally Administered Nonpathogenic Attenuated Vaccine Virus Can Be Used to Control SARS-CoV-2 Infection: A Complementary Plan B to COVID-19 Vaccination.

Authors:  Tibor Bakacs; Volker Sandig; Imre Kovesdi
Journal:  Cureus       Date:  2022-08-27

4.  Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs.

Authors:  Tibor Bakacs; Rifaat Safadi; Imre Kovesdi
Journal:  Hepatol Med Policy       Date:  2018-01-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.